Global Checkpoint Inhibitors Market to Reach $55.64 Billion by 2029, Growing at 10.1% CAGR

What Is the Expected Size and Growth Rate of the Checkpoint Inhibitors Market?
The market size of checkpoint inhibitors has seen significant growth in the past years. The market is anticipated to increase from $32.41 billion in 2024 to an estimated $37.88 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.9%. Factors contributing to the historical growth include a surge in cancer cases, heightened awareness surrounding checkpoint inhibitors, broader spectrum of approved checkpoint inhibitors, continuous research and development of new checkpoint inhibitors, and ongoing clinical trials and studies.

The size of the checkpoint inhibitors market is anticipated to witness a swift expansion in the upcoming years. It's projected to surge to $55.64 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%. Factors contributing to the growth during the forecast period include the expansion of indications, the discovery of biomarkers, combination treatments, individualized medicine, and additional indications. Key trends forecasted for this period are precision immunotherapy, combinations of immune checkpoints, the integration of cell therapy, biosimilars, and combinations of immunotherapy.

What Factors Are Fueling Growth in the Checkpoint Inhibitors Market?
The global surge in cancer cases is projected to fuel the expansion of the checkpoint inhibitors market. Cancer is an umbrella term for diseases marked by unchecked growth and spread of abnormal cells, which can potentially breach surrounding tissues and metastasize to other body parts. The upsurge in cancer cases is influenced by factors like aging populations, harmful lifestyle choices (e.g., smoking, unhealthy diet), environmental risks (like pollution, radiation), genetic factors, and infections such as HPV and Hepatitis. Checkpoint inhibitors counter proteins inhibiting immune cells, thereby allowing the immune system to detect and combat cancer cells more effectively. For instance, the American Cancer Society, a US-based professional organization, forecasted in September 2024 that by 2050, the number of cancer cases among men globally would surge by 84%, moving up from 10.3 million in 2022 to 19 million, while cancer-related fatalities are expected to soar by 93%, going up from 5.4 million in 2022 to 10.5 million. Consequently, the global increase in cancer prevalence is predicted to spark demand for checkpoint inhibitors in the market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3413&type=smp

Which Leading Companies Are Shaping the Growth of the Checkpoint Inhibitors Market?
Major companies operating in the checkpoint inhibitors market include AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Eli Lilly and Company, Sanofi S.A, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Zai Lab Limited

What Are the Major Trends Shaping the Checkpoint Inhibitors Market?
Leading firms in the checkpoint inhibitor market are spearheading the advancement of superior technologies such as oral checkpoint inhibitors. A significant number of cancer patients do not react to immune checkpoint inhibitors. An oral checkpoint inhibitor is a form of cancer immunotherapy medication intended to be ingested orally, which obstructs immune checkpoints like PD-1/PD-L1, allowing the immune system to identify and eliminate cancer cells. For instance, in September 2024, OmRx Oncology, a biopharmaceutical corporation based in the US, introduced OX-4224, an oral checkpoint inhibitor that targets the PD-1/PD-L1 pathway for non-small cell lung cancer (NSCLC). This experimental drug aims to offer a more budget-friendly option to biologic checkpoint inhibitors, amplifying global accessibility to cancer immunotherapy. A Phase 2 experiment in India will evaluate its safety and effectiveness in patients with advanced NSCLC. OmRx has the vision of widening its use to low and middle-income nations, with a focus on enhancing worldwide cancer treatment.

What Are the Key Segments of the Checkpoint Inhibitors Market?
The checkpoint inhibitors market covered in this report is segmented -

1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs
2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications
3) By End-Users: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By PD-1 Inhibitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo)
2) By PD-L1 Inhibitors: Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Avelumab (Bavencio)
3) By CTLA-4: Ipilimumab (Yervoy)
4) By Chimeric Antigen Receptor T-cell: CAR T-cell Therapy Products
5) By Other Drugs: Combination Therapies, Emerging Checkpoint Inhibitors

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Which Region Dominates the Checkpoint Inhibitors Market?
The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Is Covered In The Checkpoint Inhibitors Global Market Report?

- Market Size Analysis: Analyze the Checkpoint Inhibitors Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Checkpoint Inhibitors Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Checkpoint Inhibitors Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Checkpoint Inhibitors Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3413

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.